Sugi Predict

Sugi Predict / Targets / RAF1

RAF1

RAF proto-oncogene serine/threonine-protein kinase · P04049 · RAF1 on Sugi Atlas →

173,233 patent compounds predicted against RAF1, 111,290 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL101749 SCHEMBL101749 0.64 18/20
SCHEMBL102637 SCHEMBL102637 0.72 17/20
SCHEMBL20850 SCHEMBL20850 0.57 17/20
SCHEMBL161668 SCHEMBL161668 0.56 15/20
SCHEMBL161941 SCHEMBL161941 0.48 15/20
SCHEMBL69086 SCHEMBL69086 0.68 14/20
SCHEMBL40109 SCHEMBL40109 0.51 14/20
SCHEMBL39717 SCHEMBL39717 0.49 14/20
SCHEMBL39854 SCHEMBL39854 0.39 14/20
SCHEMBL68380 SCHEMBL68380 0.75 13/20
SCHEMBL69565 SCHEMBL69565 0.68 13/20
SCHEMBL85099 SCHEMBL85099 0.68 13/20
SCHEMBL67380 SCHEMBL67380 0.65 13/20
SCHEMBL67900 SCHEMBL67900 0.64 13/20
SCHEMBL67346 SCHEMBL67346 0.60 13/20
SCHEMBL68343 SCHEMBL68343 0.58 13/20
SCHEMBL69356 SCHEMBL69356 0.56 13/20
Sorafenib Sorafenib (SCHEMBL8218) 1.00 12/20
Gw305074X Gw305074X (SCHEMBL149921) 1.00 12/20
Gw305074X Gw305074X (SCHEMBL149922) 1.00 12/20

Clinical trials — most relevant to RAF1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma PHASE4UNKNOWN
Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer PHASE2COMPLETED
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma PHASE1/PHASE2COMPLETED
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer PHASE1/PHASE2COMPLETED
Selective Treatment According to Molecular Subtype of Prostate Cancer PHASE2UNKNOWN
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma PHASE2COMPLETED
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas PHASE1/PHASE2COMPLETED
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations PHASE2ACTIVE_NOT_RECRUITING
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma PHASE1/PHASE2COMPLETED
HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies PHASE1/PHASE2RECRUITING
Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG) PHASE2NOT_YET_RECRUITING
MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma PHASE2COMPLETED
Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer PHASE2COMPLETED
Breast Cancer Study: Paclitaxel Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment PHASE2COMPLETED
Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma PHASE2COMPLETED
Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer PHASE2COMPLETED
Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE) PHASE2WITHDRAWN
MCS110 With BRAF/MEK Inhibition in Patients With Melanoma PHASE1/PHASE2COMPLETED
A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion). PHASE1ACTIVE_NOT_RECRUITING
A Study of ASN007 in Patients With Advanced Solid Tumors PHASE1COMPLETED
LUT017 Gel for Venous Leg Ulcers and Chronic Non-Healing Skin Wounds in Adults PHASE1NOT_YET_RECRUITING
Study of LUT017 Gel to Improve Healing of Skin Wounds After Removal of Benign Lesions in Healthy Adults PHASE1NOT_YET_RECRUITING
BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors PHASE1COMPLETED
Molecular Phenotype Changes and Personalized Treatment for CRPC nanUNKNOWN
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies nanRECRUITING
Clinical Genetics Branch Eligibility Screening Survey nanNOT_YET_RECRUITING
BRAF V600-mutated Lung Carcinoma Treated With the Combination of Dabrafenib-trametinib: a Retrospective Evaluation nanCOMPLETED
Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment nanACTIVE_NOT_RECRUITING
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients nanCOMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a RAF1 binder may also engage these)

ProteinNameSimilarity
Q5R5M7 — 1.000 Q5R5M7 →
P11345 — 1.000 P11345 →
A7E3S4 — 1.000 A7E3S4 →
P09560 — 1.000 P09560 →
Q99N57 — 1.000 Q99N57 →
P05625 — 1.000 P05625 →
P34908 — 0.995 P34908 →
Q04982 — 0.990 Q04982 →
O54785 — 0.990 O54785 →
MAP3K3 Mitogen-activated protein kinase kinase kinase 3 0.989 landscape →
P28028 — 0.989 P28028 →
ARAF Serine/threonine-protein kinase A-Raf 0.988 landscape →
P11346 — 0.988 P11346 →
Q61084 — 0.988 Q61084 →
PTK2 Focal adhesion kinase 1 0.988 landscape →
Q61083 — 0.988 Q61083 →
P27966 — 0.987 P27966 →
O19004 — 0.987 O19004 →
Q62073 — 0.987 Q62073 →
Q00944 — 0.987 Q00944 →
O35346 — 0.987 O35346 →
A2VDU3 — 0.986 A2VDU3 →
P34152 — 0.986 P34152 →
P14056 — 0.986 P14056 →
P53666 — 0.986 P53666 →
LIMK2 LIM domain kinase 2 0.986 landscape →
P0C8E4 — 0.985 P0C8E4 →
MAP3K7 Mitogen-activated protein kinase kinase kinase 7 0.985 landscape →
BRAF Serine/threonine-protein kinase B-raf 0.984 landscape →
P04627 — 0.984 P04627 →